Sandoz to file for approval of aflibercept biosimilar
European Pharmaceutical Review
AUGUST 16, 2023
Sandoz has announced positive results from the MYLIGHT Phase III study for its biosimilar aflibercept, for patients living with wet macular degeneration. The confirmatory efficacy and safety study ( NCT04864834 ) demonstrated therapeutic equivalence between the biosimilar aflibercept and the reference biologic, Eylea®.
Let's personalize your content